πŸ‡ΊπŸ‡Έ FDA
Patent

US 8841333

Methods for treating nephrolithiasis

granted A61KA61K31/415A61K31/426

Quick answer

US patent 8841333 (Methods for treating nephrolithiasis) held by Takeda Pharmaceuticals U.S.A., Inc. expires Mon Sep 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceuticals U.S.A., Inc.
Grant date
Tue Sep 23 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K31/415, A61K31/426, A61P, A61P13/12